IL218392A - Pharmaceutical combination, its use in the treatment of tumors, a commercial package comprising it and use of a fatty acid derivative for manufacturing a pharmaceutical composition for treating mucositis - Google Patents

Pharmaceutical combination, its use in the treatment of tumors, a commercial package comprising it and use of a fatty acid derivative for manufacturing a pharmaceutical composition for treating mucositis

Info

Publication number
IL218392A
IL218392A IL218392A IL21839212A IL218392A IL 218392 A IL218392 A IL 218392A IL 218392 A IL218392 A IL 218392A IL 21839212 A IL21839212 A IL 21839212A IL 218392 A IL218392 A IL 218392A
Authority
IL
Israel
Prior art keywords
treatment
mucositis
sham
drug
preparation
Prior art date
Application number
IL218392A
Other languages
English (en)
Hebrew (he)
Other versions
IL218392A0 (en
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of IL218392A0 publication Critical patent/IL218392A0/en
Publication of IL218392A publication Critical patent/IL218392A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL218392A 2009-09-16 2012-02-29 Pharmaceutical combination, its use in the treatment of tumors, a commercial package comprising it and use of a fatty acid derivative for manufacturing a pharmaceutical composition for treating mucositis IL218392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Publications (2)

Publication Number Publication Date
IL218392A0 IL218392A0 (en) 2012-04-30
IL218392A true IL218392A (en) 2016-05-31

Family

ID=43730802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218392A IL218392A (en) 2009-09-16 2012-02-29 Pharmaceutical combination, its use in the treatment of tumors, a commercial package comprising it and use of a fatty acid derivative for manufacturing a pharmaceutical composition for treating mucositis

Country Status (17)

Country Link
US (3) US9084815B2 (enExample)
EP (1) EP2477632A4 (enExample)
JP (2) JP5891168B2 (enExample)
KR (1) KR101760963B1 (enExample)
CN (2) CN107050458A (enExample)
AR (1) AR078182A1 (enExample)
AU (1) AU2010296307B2 (enExample)
BR (1) BR112012005896A2 (enExample)
CA (1) CA2772314A1 (enExample)
IL (1) IL218392A (enExample)
MX (1) MX2012003188A (enExample)
NZ (1) NZ598618A (enExample)
RU (2) RU2577700C2 (enExample)
SG (2) SG10201405467PA (enExample)
TW (1) TWI535436B (enExample)
WO (1) WO2011034210A1 (enExample)
ZA (1) ZA201201894B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
ES2099736T3 (es) 1990-04-27 1997-06-01 R Tech Ueno Ltd Utilizacion de derivados de la 15-deshidroxi-16-oxoprostaglandina en el tratamiento de las alergias.
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
NZ521464A (en) 2000-03-24 2004-09-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
BRPI0607084A2 (pt) 2005-01-27 2009-08-04 Sucampo Ag uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Also Published As

Publication number Publication date
CN107050458A (zh) 2017-08-18
EP2477632A4 (en) 2013-06-12
US9084815B2 (en) 2015-07-21
AU2010296307B2 (en) 2016-02-11
RU2016103415A (ru) 2018-11-22
SG179153A1 (en) 2012-04-27
JP2013504520A (ja) 2013-02-07
MX2012003188A (es) 2012-04-30
EP2477632A1 (en) 2012-07-25
NZ598618A (en) 2014-10-31
JP5891168B2 (ja) 2016-03-22
RU2577700C2 (ru) 2016-03-20
KR101760963B1 (ko) 2017-07-24
CA2772314A1 (en) 2011-03-24
TWI535436B (zh) 2016-06-01
US20170079986A1 (en) 2017-03-23
SG10201405467PA (en) 2014-10-30
TW201116277A (en) 2011-05-16
AR078182A1 (es) 2011-10-19
AU2010296307A1 (en) 2012-04-05
KR20120081139A (ko) 2012-07-18
ZA201201894B (en) 2012-11-28
US20110064748A1 (en) 2011-03-17
IL218392A0 (en) 2012-04-30
JP2016056191A (ja) 2016-04-21
WO2011034210A1 (en) 2011-03-24
BR112012005896A2 (pt) 2016-03-15
US20150272961A1 (en) 2015-10-01
CN102481302A (zh) 2012-05-30
RU2012114771A (ru) 2013-10-27

Similar Documents

Publication Publication Date Title
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
PL2588091T3 (pl) Sposoby dostarczania medycznej substancji czynnej poprzez podawanie wyrobów do higieny osobistej zawierających filament
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
HUE037735T2 (hu) DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
BRPI1010836A2 (pt) nutrição medicinal especializada para pacientes cirúrgicos e de trauma contendo probióticos
IT1401173B1 (it) Contenitore richiudibile per prodotti fluidi, particolarmente per prodotti medicali, farmaceutici e cosmetici
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
PT2582728T (pt) Conjugados fármaco-anticorpo humano contra fator tecidual
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
DK2895279T3 (da) Desinficering, sterilisering og emballering af spiseklare produkter
GB2486161B (en) Disposable hangable animal food dispenser
HUE053409T2 (hu) Ortopédiai szék a gerincbetegségek kezelésére és megelõzésére
PT2632300T (pt) Almofada cervical para o tratamento de doenças da coluna cervical
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
HUE043063T2 (hu) Gyógyászati termék és kezelés
IT1393560B1 (it) Contenitore per prodotti fluidi, particolarmente prodotti farmaceutici, cosmetici, medicali o simili
EA201291294A1 (ru) Изомальтулоза для применения для усиления умственной деятельности
HUE055440T2 (hu) Élelmiszerhigiéniai eljárás és élelmiszertermék
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees